142 related articles for article (PubMed ID: 21491667)
1. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
Armitage JO; Hsi ED; Foss FM
Clin Adv Hematol Oncol; 2010 Dec; 8(12 Suppl 22):1-15. PubMed ID: 21491667
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. [Peripheral T-cell lymphoma: diagnosis and treatment].
Reimer P; Hentrich M
Dtsch Med Wochenschr; 2006 Mar; 131(13):685-90. PubMed ID: 16555177
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
[TBL] [Abstract][Full Text] [Related]
5. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
6. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
7. [Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen].
Huang HQ; Peng YL; Lin XB; Sun XF; Lin TY; Xia ZJ; Li YH; Cai QQ; He YJ; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Nov; 23(11 Suppl):1443-7. PubMed ID: 15566653
[TBL] [Abstract][Full Text] [Related]
8. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
Vose J; Armitage J; Weisenburger D;
J Clin Oncol; 2008 Sep; 26(25):4124-30. PubMed ID: 18626005
[TBL] [Abstract][Full Text] [Related]
9. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
10. [Recent progress in the treatment of malignant lymphoma].
Tobinai K; Shimoyama M
Gan To Kagaku Ryoho; 1994 Jul; 21(8):1151-6. PubMed ID: 8031155
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of primary mediastinal large B-cell lymphomas].
Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
[TBL] [Abstract][Full Text] [Related]
12. Aggressive non-Hodgkin's lymphoma: T-cell versus B-cell.
Liang R; Todd D; Ho FC
Hematol Oncol; 1996 Mar; 14(1):1-6. PubMed ID: 8613131
[TBL] [Abstract][Full Text] [Related]
13. Clinical roundtable monograph. The management of aggressive T-cell lymphoma: a discussion on transformed mycosis fungoides.
Horwitz SM; Duvic M; Hsi ED
Clin Adv Hematol Oncol; 2010 Dec; 8(12):1-15. PubMed ID: 21344783
[TBL] [Abstract][Full Text] [Related]
14. New drug therapies in peripheral T-cell lymphoma.
Howman RA; Prince HM
Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of a primary gastric T-cell lymphoma lacking the human T-cell leukemia virus type 1.
Yachida S; Sasako M; Tobinai K; Matsuno Y; Shimoda T
Hepatogastroenterology; 2010; 57(98):383-7. PubMed ID: 20583449
[TBL] [Abstract][Full Text] [Related]
16. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
[TBL] [Abstract][Full Text] [Related]
17. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Simon A; Peoch M; Casassus P; Deconinck E; Colombat P; Desablens B; Tournilhac O; Eghbali H; Foussard C; Jaubert J; Vilque JP; Rossi JF; Lucas V; Delwail V; Thyss A; Maloisel F; Milpied N; le Gouill S; Lamy T; Gressin R
Br J Haematol; 2010 Oct; 151(2):159-66. PubMed ID: 20738307
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
[TBL] [Abstract][Full Text] [Related]
19. Current treatment of peripheral T-cell lymphoma.
Horwitz SM; Coiffier B; Hsi ED; Pro B
Clin Adv Hematol Oncol; 2011 Aug; 9(8 Suppl 16):1-15. PubMed ID: 22361915
[TBL] [Abstract][Full Text] [Related]
20. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
